Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2022 Jul 1;10(7):856–870. doi: 10.1158/2326-6066.CIR-21-0501

Table 2.

Count and Proportion of Subjects with CRS and Neurotoxicity Adverse Events Related to CAR T Cell Infusion

Adverse Events of Interest Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Cytokine Release Syndrome
 SCRI-CAR19v1 (n=43) 39.5%
(17)
48.8%
(21)
4.7%
(2)
0 0
 SCRI-CAR19v2 (n=21) 19%
(4)
57%
(12)
0 0 0
Neurotoxicity
 SCRI-CAR19v1 (n=43) 14%
(6)
16%
(7)
9%
(4)
9%
(4)
0
 SCRI-CAR19v2 (n=21) 0 14%
(3)
10%
(2)
10%
(2)
5%
(1)